{
  "id": 20243517,
  "title": "Zimmer Biomet group president Kevin Thornal sells $528,978 in stock",
  "url": "https://urgent.news/2026/11/16/zimmer-biomet-group-president-kevin-thornal-sells-528-978-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T00:01:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/zimmer-biomet-group-president-kevin-thornal-sells-528978-in-stock-93CH-5028214"
  },
  "original_language": "en",
  "account": "Kevin Thornal, President of Zimmer Biomet Holdings, Inc., divested 5,691 shares of the company's stock on September 11, 2026, totaling $528,978. He disposed of the shares at $92.95 each, bringing his ownership to zero beneficial shares in ZIMMER BIOMET HOLDINGS, INC. The insider sale transpired as Zimmer Biomet's shares are trading at $103.21, marking an increase of approximately 11% from the sale price. Analysts view the stock as undervalued, with a Fair Value of $121.36. Zimmer Biomet boasts a robust market cap of $19.5 billion and generated $8.57 billion in revenue over the past year. The company has been actively executing strategies, such as a substantial share buyback program. Zimmer Biomet's latest quarter reported revenue of $2.06 billion, surpassing expectations, and adjusted earnings per share of $1.90, exceeding forecasts. Consequently, the firm raised its projected earnings for the year. Following the positive earnings report, several investment firms adjusted their price targets for ZBH, including Stifel, Jefferies, Truist Securities, and BMO Capital.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}